Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the publication of new scientific advances important for identifying…
Read More
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the publication of new scientific advances important for the…
Hamlet BioPharma’s extensive patent portfolio comprises 147 granted patents and 33 pending cases. Strategy regarding intellectual property rights, follow up and extension of filed cases…
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces that Hamlet BioPharma’s drug candidate Alpha1H has shown potent…
Som tidigare meddelats bjuder Hamlet BioPharma in till månatligt investerarmöte onsdagen den 12 mars, 2025, klockan 12.00. Klicka på länken nedan för a7 delta på…
Vid extra bolagsstämma i Hamlet BioPharma AB (publ), org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) idag den 11 mars 2025 fattades bland annat följande beslut. Samtliga…
Med anledning av Pressmeddelanden och nyheter bjuder Hamlet BioPharma in till investerarmöte fredagen den 21 februari, 2025, klockan 12.00. Bolaget kommer att beskriva utvecklingen av…
Aktieägarna i Hamlet BioPharma AB (publ) (”Hamlet BioPharma” eller ”Bolaget”), org.nr 556568-8958, kallas härmed till extra bolagsstämma tisdagen den 11 mars 2025 kl. 11:00 i…
Hamlet BioPharma AB (“Hamlet BioPharma” or the “Company”), an innovative pharmaceutical company that develops new therapies against cancer and infections, announces that the Company’s board…
Hamlet BioPharma has appointed Elisabeth Parker, PhD to strengthen the business development expertise in the company. Dr. Parker has 25 years’ experience of R&D, partnering…